Plus Therapeutics Files Definitive Proxy Statement
Ticker: PSTV · Form: DEF 14A · Filed: Apr 10, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | DEF 14A |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Plus Therapeutics filed its proxy statement - shareholders vote soon on company matters.
AI Summary
Plus Therapeutics, Inc. filed its definitive proxy statement on April 10, 2025, for its annual meeting of stockholders. The filing, under the 1934 Securities Exchange Act, details the company's governance and proposals to be voted on by shareholders. The company was formerly known as Cytori Therapeutics, Inc. and Macropore Inc.
Why It Matters
This filing provides shareholders with crucial information regarding company management, board elections, and other important proposals, enabling them to make informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.
Key Numbers
- 20250410 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
- 20250502 — Period of Report (The period the proxy statement pertains to, likely the upcoming annual meeting date.)
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- CYTORI THERAPEUTICS, INC. (company) — Former company name
- MACROPORE INC (company) — Former company name
- Securities Exchange Act of 1934 (legal_document) — Governing legislation for the filing
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is filed by a company to provide shareholders with information about matters to be voted on at an upcoming shareholder meeting, such as the election of directors and executive compensation.
When was Plus Therapeutics, Inc. formerly known as Cytori Therapeutics, Inc. and Macropore Inc.?
Plus Therapeutics, Inc. was formerly known as Cytori Therapeutics, Inc. after a name change on July 12, 2005, and prior to that, it was known as Macropore Inc. after a name change on March 20, 2001.
What is the filing date of this proxy statement?
The definitive proxy statement was filed on April 10, 2025.
What is the fiscal year end for Plus Therapeutics, Inc.?
The fiscal year end for Plus Therapeutics, Inc. is December 31.
Where is Plus Therapeutics, Inc. headquartered?
Plus Therapeutics, Inc. is headquartered at 4200 Marathon Blvd., Suite 200, Austin, TX 78756.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 10, 2025 regarding PLUS THERAPEUTICS, INC. (PSTV).